Last reviewed · How we verify

NCT05289895

Prognostic Biomarkers of Pancreatic Cancer Based on Proteomic Techniques

Status unknown Last updated 22 March 2022
What this trial tests

trial testing No intervention in Proteomics in 220 participants. Status unknown.

Timeline
1 April 2022
Primary endpoint
1 March 2023
30 December 2024

Quick facts

Lead sponsorThe Affiliated Hospital of Qingdao University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment220
Start date1 April 2022
Primary completion1 March 2023
Estimated completion30 December 2024

Drugs / interventions tested

Conditions studied

Sponsor

The Affiliated Hospital of Qingdao University

Who can join

Eligibility, any sex, with Proteomics or Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sequence I (Retrospective study: proteomic analysis of pathological specimens and information collection of previous patients with pancreatic cancer) Sequence 2 (Non-interventional prospective study, sample and information collection in patients with pancreatic cancer) Sequence 3 (Non-intervention study, healthy subjects sample and information collection)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Proteomics

Currently open trials in the same condition.

Other The Affiliated Hospital of Qingdao University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05289895.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing